Research Pipeline

With many potential new therapies currently in clinical trials, our goal is to be the industry leader in specialty care. We remain focused on discovering scientific breakthroughs to address complex, debilitating diseases.

Explore highlights of our research and development pipeline across our five areas of focus.

Items marked with ^ are being developed in collaboration with Regeneron, * are being developed in collaboration with Alnylam®, ❅ are being developed in collaboration with Sangamo Therapeutics and ♦ are being developed in collaboration with Principia Biopharma Inc. Items shown with a ✜ denote a Phase 1/2 trial. Items shown with a † denote a Phase 2/3 trial. Items shown with ▼ denote the INN in the US is cemiplimab-rwlc.

Product Candidate	Technology	Phase I	Phase II	Phase III	Current Phase
Rare Diseases
Avalglucosidase alfa Pompe disease	protein-based therapy				PHASE III
Venglustat Autosomal Dominant Polycystic Kidney Disease	small molecule				PHASE III
Eliglustat Gaucher Type 1, switch from ERT - Pediatric	small molecule				PHASE III
Olipudase Alfa† Acid Sphingomyelinase Deficiency (ASMD)	protein-based therapy				PHASE II
Venglustat Fabry disease	small molecule				PHASE II
SAR339375 Alport Syndrome	RNAi				PHASE II
Venglustat Parkinson's disease with a GBA mutation	small molecule				PHASE II
Venglustat Gaucher Type 3	small molecule				PHASE II
Rare Blood Disorders
Fitusiran* Hemophilia A & B	RNAi				PHASE III
Sutimlimab Cold Agglutinin Disease	mAb to C1s				PHASE III
BIVV001✜ Hemophilia A	Extended Half Life Factor				PHASE I/2
ST-400✜ Beta Thalassemia	ZFN Gene Editing				PHASE I/2
BIVV003❅ Sickle Cell Disease	ZFN Gene Editing				PHASE I/2
Multiple Sclerosis
SAR442168♦ Multiple Sclerosis	BTK inhibitor				PHASE I
Oncology
Isatuximab Relapsing Refractory Multiple Myeloma (IKEMA)	mAb	$Isatuximab Relapsing Refractory Multiple Myeloma - Phase I - 100% of progress$	$Isatuximab Relapsing Refractory Multiple Myeloma - Phase II - 100% of progress$	$Isatuximab Relapsing Refractory Multiple Myeloma - Phase III - 50% of progress$	PHASE III
Isatuximab Newly Diagnosed Multiple Myeloma	mAb				PHASE III
Isatuximab 1L Newly Diagnosed Multiple Myeloma (IMROZ)	mAb				PHASE III
Isatuximab 3L Relapsing Refractory Multiple Myeloma (ICARIA)	mAb	$Isatuximab 3L Relapsing Refractory Multiple Myeloma (ICARIA) - Phase I - 100% of progress$	$Isatuximab 3L Relapsing Refractory Multiple Myeloma (ICARIA) - Phase II - 100% of progress$	$Isatuximab 3L Relapsing Refractory Multiple Myeloma (ICARIA)- Phase III - 25% of progress$	PHASE III
Cemiplimab^▼ 1L Non-small Cell Lung Cancer	mAb				PHASE III
Cemiplimab^▼ 2L Cervical Cancer	mAb				PHASE III
Cemiplimab^▼ + Chemotherapy 1L Non-small Cell Lung Cancer	mAb				PHASE III
Cemiplimab^▼ Advanced BCC	mAb				PHASE II
Isatuximab + Cemiplimab^▼ Relapsing Refractory Multiple Myeloma	mAb	$isatuximab + Cemiplimab^ Relapsing Refractory Multiple Myeloma - Phase I - 100% of progress$	$isatuximab + Cemiplimab^ Relapsing Refractory Multiple Myeloma - Phase II - 50% of progress$	$isatuximab + Cemiplimab^ Relapsing Refractory Multiple Myeloma - Phase III - 0% of progress$	PHASE II
Isatuximab + Cemiplimab^▼ Advanced Malignancies	mAb				PHASE II
Isatuximab + Cemiplimab^▼ Lymphoma	mAb				PHASE II
Isatuximab + atezolizumab Advanced Malignancies	mAb				PHASE II
Isatuximab + atezolizumab Solid Tumors	mAb				PHASE II
SAR439459 (TGFβ) Advanced Solid Tumors	mAb				PHASE I
SAR408701 (CEACAM5) Solid tumors	mAb				PHASE I
REGN5458 Relapsing Refractory Multiple Myeloma	mAb	$REGN5458 Relapsing Refractory Multiple Myeloma - Phase I - 50% of progress$	$REGN5458 Relapsing Refractory Multiple Myeloma - Phase II - 0% of progress$	$REGN5458 Relapsing Refractory Multiple Myeloma - Phase III - 0% of progress$	PHASE I
REGN4018 Ovarian Cancer	mAb				PHASE I
SAR442720 Solid tumors	mAb				PHASE I
SAR440234 Leukemia	mAb				PHASE I
SAR441000 Melanoma	mAb				PHASE I
cemiplimab + REGN4018 Ovarian Cancer	mAb				PHASE I
SAR439859 (SERD) Metastatic Breast Cancer	mAb				PHASE I
Immunology
Dupilumab^ Atopic Dermatitis (12-17 years old)	mAb				PHASE III
Dupilumab^ Nasal Polyposis	mAb				PHASE III
Dupilumab^ Atopic Dermatitis (6-11 years old)	mAb				PHASE III
Dupilumab^ Atopic Dermatitis (6 mo - 5 years old)	mAb				PHASE III
Dupilumab^ Asthma (6-11 years old)	mAb				PHASE III
Dupilumab^ Eosinophilic Esophagitis	mAb				PHASE III
Sarilumab^ Giant Cell Arteritis	mAb				PHASE III
Sarilumab^ Polymyalgia Rheumatica	mAb				PHASE III
Dupilumab^ Grass Immunotherapy	mAb				PHASE II
Dupilumab^ + AR101 Peanut Allergy - Pediatric	mAb				PHASE II
SAR440340^ Asthma	mAb				PHASE II
SAR440340^ COPD	mAb				PHASE II
Sarilumab^ Polyarticular Juvenile Idiopathic Arthritis	mAb				PHASE II
Sarilumab^ Systemic Juvenile Arthritis	mAb				PHASE II
SAR156597^ Systemic Scleroderma	mAb				PHASE II

The agents mentioned here are investigational and have not been approved by the US Food and Drug Administration (FDA) or any other regulatory agency worldwide for the uses under investigation.

In addition to the candidates in clinical development, we are conducting earlier stage research in a range of therapeutic areas including genetic diseases such as cystic fibrosis, spinal muscular atrophy, and Lebers congenital amaurosis type 1. We have several programs in multiple sclerosis with molecules addressing areas of unmet need, using approaches such as immunomodulation, neuroprotection, and remylination.

Avalglucosidase alfa clinical trial

Learn more about the ongoing phase 3 clinical trial for avalglucosidase alfa, an investigational enzyme replacement therapy being studied for the treatment of Pompe disease.

Sanofi’s R&D portfolio

The full Sanofi research pipeline focuses on finding innovative solutions to a variety of major public health challenges.